Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F, Haas R, Kobbe G, Fenk R. Korthals M, et al. Among authors: bruns i. Biol Blood Marrow Transplant. 2012 Mar;18(3):423-431.e3. doi: 10.1016/j.bbmt.2011.07.002. Epub 2011 Jul 13. Biol Blood Marrow Transplant. 2012. PMID: 21745451 Free article.
Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma.
Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F, Ruf L, Haas R, Kobbe G. Fenk R, et al. Among authors: bruns i. Exp Hematol. 2006 Oct;34(10):1296-302. doi: 10.1016/j.exphem.2006.06.002. Exp Hematol. 2006. PMID: 16982322 Free article.
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, Galonska L, Kondakci M, Weigelt C, Fenk R, Germing U, Haas R, Kobbe G. Saure C, et al. Among authors: bruns i. Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29. Biol Blood Marrow Transplant. 2012. PMID: 21963618 Free article. Clinical Trial.
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.
Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hünerlitürkoglu AN, Zilkens C, Jäger M, Steidl U, Zohren F, Fenk R, Kobbe G, Brors B, Czibere A, Schroeder T, Trumpp A, Haas R. Bruns I, et al. Blood. 2012 Sep 27;120(13):2620-30. doi: 10.1182/blood-2011-04-347484. Epub 2012 Apr 18. Blood. 2012. PMID: 22517906 Free PMC article.
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Zohren F, Czibere A, Bruns I, Fenk R, Schroeder T, Gräf T, Haas R, Kobbe G. Zohren F, et al. Among authors: bruns i. Bone Marrow Transplant. 2009 Dec;44(12):785-92. doi: 10.1038/bmt.2009.83. Epub 2009 May 11. Bone Marrow Transplant. 2009. PMID: 19430496 Clinical Trial.
Bendamustine in patients with relapsed or refractory multiple myeloma.
Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R. Michael M, et al. Among authors: bruns i. Eur J Med Res. 2010 Jan 29;15(1):13-9. doi: 10.1186/2047-783x-15-1-13. Eur J Med Res. 2010. PMID: 20159666 Free PMC article.
75 results